Profil
Dr. René Muttenzer is on the Board of Directors at Polyphor AG and Molecular Health AG.
Dr. Muttenzer was previously employed as a Principal by Novartis AG.
He also served on the board at Acino Holding AG.
He received his graduate degree from the University of Basel.
Anciens postes connus de René Muttenzer
| Sociétés | Poste | Fin |
|---|---|---|
| ACINO HOLDING AG | Directeur/Membre du Conseil | 31/03/2012 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Posbelduf Biotech AG
 Posbelduf Biotech AG Pharmaceuticals: MajorHealth Technology Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - |
| SPEXIS AG | Directeur/Membre du Conseil | - |
Formation de René Muttenzer
| University of Basel | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPEXIS AG | Health Technology |
| NOVARTIS AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Acino International AG
 Acino International AG Pharmaceuticals: MajorHealth Technology Acino International AG develops and manufactures pharmaceuticals in novel drug delivery form. The firm provides drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. It offers abelcet, bactiflox, clopacin, dolonica, hydronica, neurorubine, olfen and spasfon. The company was founded in 1836 and is headquartered in Zurich, Switzerland. | Health Technology |
Posbelduf Biotech AG
Posbelduf Biotech AG Pharmaceuticals: MajorHealth Technology Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland. | Health Technology |
